Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $69,825 | $186,922 | $207,520 | $429,837 |
| - Cash | $12,474 | $25,291 | $30,605 | $31,828 |
| + Debt | $18,025 | $16,888 | $1,832 | $1,740 |
| Enterprise Value | $75,376 | $178,519 | $178,747 | $399,749 |
| Revenue | $7,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $7,000 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$137,942 | -$131,108 | -$122,216 | -$112,820 |
| % Margin | -1,970.6% | – | – | – |
| Net Income | -$127,173 | -$121,832 | -$115,438 | -$111,694 |
| % Margin | -1,816.8% | – | – | – |
| EPS Diluted | -1.68 | -2.02 | -2.27 | -2.33 |
| % Growth | 16.8% | 11% | 2.6% | – |
| Operating Cash Flow | -$102,888 | -$107,063 | -$83,729 | -$83,531 |
| Capital Expenditures | -$764 | -$3,513 | -$3,019 | -$2,323 |
| Free Cash Flow | -$103,652 | -$110,576 | -$86,748 | -$85,854 |